QIAGEN Acquires DxS Ltd -- Creating Leadership in Personalized Healthcare Sep 23, 2009
VENLO, The Netherlands, Sept. 22, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq: - ) (Frankfurt: - ) today announced that it has acquired DxS Ltd (DxS), a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, United Kingdom ... QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies ... The QIAGEN N.V. logo is available at. (Primezone Releases)
QIAGEN Announces An Offering of New Common Shares Sep 23, 2009
VENLO, The Netherlands, Sept. 22, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq: - ) (Frankfurt: - ) (the "Company") announces today the launch of a placement of up to 27 ... Subject to approval by the AFM, a prospectus relating to the listing of the Shares on the Frankfurt Stock Exchange is expected to be published on or about September 23, 2009 by being made available to the public, free of charge, in printed form at the registered office of QIAGEN N.V., Spoorstraat 50, 5911 KJ Venlo, the... (Primezone Releases)
QIAGEN's New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatrica's SampleMatrix(R) Technology Sep 10, 2009
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. (PR Newswire)
QIAGEN Transfers Distribution Rights for Transplantation Testing Product Portfolio and Related Assets to LinkMed Jun 16, 2009
Press Release Source: QIAGEN N.V. ... VENLO, The Netherlands, June 16, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq: - ; Frankfurt: - ) today announced that it has signed an agreement to transfer distribution rights on July 1, 2009 for the Olerup SSP(r) product line and the related assets to Olerup International AB, a subsidiary of LinkMed (Nasdaq: - ), a Swedish venture capital company specializing in Life Sciences ... QIAGEN N.V., a Netherlands holding company, is the leading global provider... (Primezone Releases)
Appeals court dismisses Third Wave case Apr 3, 2009
Third Wave, a developer of genetic analysis products for clinical applications and now a subsidiary of (NASDAQ: HOLX), was sued in January 2007 by Digene Corp., which has since been acquired by Qiagen N.V. Digene alleged that Third Wave infringes a Digene patent related to the human papillomavirus, or HPV. Third Wave responded by denying infringement and filing the countersuit against Digene. As for the initial patent infringement case filed by Digene (Qiagen) against Third Wave, the court... (Milwaukee Business Journal, WI)
